#TEXAS RETINA ASSOCIATES LUBBOCK TRIAL#

#TEXAS RETINA ASSOCIATES LUBBOCK TRIAL#

Verteporfin in Photodynamic Therapy (VIP) Study Group, Blinder KJ, Blumendranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LF, Slakter JS, Strong HA, Virgili G, Williams GA Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia: 2-year Results of a Randomized Clinical Trial – VIP Report #3.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Group, Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wendenstern A Photodynamic Therapy of Subfoveal Choroidal Neovascularization with Verteporfin: Fluorescein Angiographic Guidelines for Evaluation and Treatment – TAP and VIP Report #2.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Group, Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donato G, Hao Y, Ma C, Menchini U, Miller JW, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Strong HA, Stur M, Su XY Effect of Lesion Size, Visual Acuity, and Lesions Composition on Visual Acuity Change With and Without Verteporfin Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: TAP and VIP Report #1.Eyetech Study Group, Anti-vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Phase II Study Results.

Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Verteporfin in Photodynamic Therapy (VIP) Study Group, Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW, Mones J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter JS, Schmidt-Erfurth U, Sorenson JA Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Meta-analysis of 2-year Safety Results in Three Randomized Clinical Trials: Treatment Of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no.

Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M, Slakter JS, Soubrane G, Strong HA, Stur M Acute Sever Visual Acuity Decrease after Photodynamic Therapy with Verteporfin: Case Reports from Randomized Clinical Trials – TAP and VIP report no.

A Randomized, Placebo-controlled Clinical Trial of Docosahexaenoic Acid Supplementation for X-linked Retinitis Pigmentosa. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG.

Texas retina associates lubbock